Clinical trials: Breast Cancer, Female
Breast Cancer
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor.
- Trial name
- NCT00045591
- Testing
- celecoxib
- Where
- 74 sites in United States
- Volunteers
- 39 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Melanoma, Gastrointestinal Cancer
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
Background: Exomes are the parts of deoxyribonucleic acid (DNA) that make proteins. Researchers are finding a way to read the letters in the exome. Incorrect letters are called mutations. Tumors contain specific mutations.
- Conditions
- Melanoma, Gastrointestinal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT03300843
- Testing
- Peptide loaded dendritic cell vaccine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Menopausal Symptoms
Acupuncture or Medication in Reducing Pain in Postmenopausal Women With Breast Cancer and Joint Pain
RATIONALE: Acupuncture may reduce joint pain in postmenopausal women with breast cancer. It is not yet known whether acupuncture is more effective than standard therapy analgesics in decreasing joint pain caused by aromatase…
- Conditions
- Breast Cancer, Menopausal Symptoms, Pain
- Trial name
- NCT00892268
- Testing
- acupuncture therapy, pain therapy
- Volunteers
- 68 people
- Sponsor
- University of Arizona
Breast Cancer
Perillyl Alcohol in Preventing Recurrent Breast Cancer in Women Who Have Been Treated With Surgery With or Without Adjuvant Therapy
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the recurrence of cancer. The use of perillyl alcohol may be effective in preventing the recurrence of breast cancer.
- Trial name
- NCT00022425
- Testing
- perillyl alcohol
- Where
- United States
- Sponsor
- The Cleveland Clinic
Solid Tumors
Cardiac Safety Assessment Study of Picoplatin in Solid Tumors
The purpose of this study is to investigate what effects, if any, picoplatin has on the heart rhythm.
- Trial name
- NCT00710697
- Testing
- Picoplatin
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Poniard Pharmaceuticals
Breast Cancer Female
Prognostic Value of Some Biochemical Markers in Breast Cancer
breast cancer is the most common type of cancer in women and first cause of cancer death among them. in Egypt it constitutes 33% of female cancer cases and more than22000 new cases diagnosed each year.
- Trial name
- NCT05699577
- Testing
- serum sample for ELIZA
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Sohag University
Breast Neoplasms
Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms
To evaluate the preliminary activity and pharmacokinetics of 2 separate doses and schedules of orally administered Temsirolimus (CCI-779) given in combination with daily letrozole, compared to letrozole alone, in the treatment of…
- Trial name
- NCT00062751
- Testing
- Letrozole / Temsirolimus (CCI-779), Letrozole
- Volunteers
- 108 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Breast Cancer
Assessing the Sensitivity of "SureTouch™" in Women Undergoing Diagnostic and Screening Mammography
Prospective, case-control study being conducted to determine the sensitivity of the SureTouch device in detecting known masses at a pre-determined level of specificity.
- Trial name
- NCT04397029
- Testing
- SureTouch
- Where
- United States
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- George Washington University
Breast Cancer, Hodgkin's Disease
Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease
The purpose of this study is to determine if the use of breast MRI in detecting breast malignancies in survivors of Hodgkin's disease is more successful than the traditional mammogram.
- Trial name
- NCT00165412
- Testing
- breast MRI, Mammogram
- Where
- 3 sites in United States
- Volunteers
- 148 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Metastatic
Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers
retrospective/prospective observational study. Objective of the study is to evaluate the effect of drugs in terms of objective responses, disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), and…
- Conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Metastatic, Ovarian Cancer, Cervical Carcinoma
- Trial name
- NCT06800612
- Testing
- Oncologic drugs administered for treatment of breast cancer, Oncologic drug administered for treatment of gynecologic cancer
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Modified Radical Mastectomy, Breast Cancer
Comparison Between Erector Spinae Plane Block Versus Serratus Anterior Plane Block Regarding Analgesia Post Modified Radical Mastectomy
The goal of this clinical trial is to compare Ultrasound Guided Erector Spinae and Ultrasound Guided Serratus Anterior Plane Block post Modified Radical Mastectomy in adult females.
- Trial name
- FMASUMD66/2025 (NCT06947330)
- Testing
- Unilateral Erector Spinae group, Unilateral Serratus Anterior group
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Kholoud Usama
Breast Cancer, Prostate Cancer
Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
The primary objective of the study is to test a new radiotracer called 68Ga-NOTA-AE105 for PET imaging of uPAR (urokinase plasminogen activator receptor).
- Conditions
- Breast Cancer, Prostate Cancer, Urinary Bladder Cancer
- Trial name
- uPAR-PET (NCT02437539)
- Testing
- Injection of 68Ga-NOTA-AE105, Positron Emission Tomography scans
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Breast Cancer
Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer
This is a study to determine the prevalence and severity of alopecia (hair loss) experienced by postmenopausal breast cancer patients receiving endocrine therapy including Tamoxifen, Letrozole (Femara), Exemestane (Aromasin), or…
- Trial name
- NCT01300871
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Breast Cancer, Hot Flashes
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
RATIONALE: St. John's wort may help relieve hot flashes in women with breast cancer. PURPOSE: This phase II trial is studying how well St. John's wort works in relieving hot flashes in women with non-metastatic breast cancer.
- Trial name
- NCT00110136
- Testing
- St. John's Wort
- Where
- 19 sites in United States
- Volunteers
- 9 people
- Sponsor
- Wake Forest University Health Sciences
Breast Neoplasm Female, Lymphoma
Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study
Breast cancer is the most common cancer among women worldwide. Similarly, Hodgkin and non- Hodgkin lymphomas make up two of the most prevalent cancers in men and women.
- Conditions
- Breast Neoplasm Female, Lymphoma, Cardiotoxicity, Anthracyclines
- Trial name
- NCT03850171
- Testing
- Exercise Training
- Where
- 4 sites in Switzerland
- Volunteers
- 57 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Epiphora
Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel
Objective: To evaluate the safety and efficacy of topical cyclosporine eye drops (Restasis®) for the treatment of epiphora caused by canalicular stenosis secondary to Docetaxel (Taxotere®) treatment for various cancers.
- Trial name
- NCT00824811
- Testing
- Cyclosporine Eye Drops (Restasis), Lubricant Eye Drops (Refresh Endura™), Fluorometholone Eye Drops (FML Forte®)
- Sponsor
- M.D. Anderson Cancer Center
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
Doctors leading this study would like to learn about providing cancer treatment/therapies to Nigerian women with breast cancer based on their human epidermal growth factor receptor 2 (HER2) status.
- Conditions
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer
- Trial name
- NCT06348134
- Testing
- Trastuzumab emtansine, Pertuzumab Injection, Docetaxel
- Where
- 4 sites in Nigeria
- Volunteers
- 74 people
- Sponsor
- University of Chicago
Breast Cancer
Promoting Weight Loss Through Diet and Exercise in Overweight Women With Breast Cancer
The investigators aim to evaluate the effect of a 6-month intervention (counseling) focused on weight loss in a group of overweight or obese women previously treated for early breast cancer.
- Trial name
- InForma (NCT02622711)
- Testing
- DI, PAI, PADI
- Where
- Italy
- Volunteers
- 262 people
- Sponsor
- European Institute of Oncology
BRCA1 Mutation, BRCA2 Mutation
Management of Women With BRCA1/2 Mutation
The aim of this study is to determine general practitionners' role in management of women with BRCA1/2 mutation. This study will be conduct between April 2017 and December 2017 at Montpellier University Hospital on women…
- Trial name
- NCT03211611
- Testing
- Questionnaire given to the two groups
- Where
- France
- Volunteers
- 600 people
- Sponsor
- University Hospital, Montpellier
Breast Cancer
Genetic Risk Estimations for Influencing Decision Making in Women at High Risk of Breast Cancer, GENRE 2 Study
The primary aim of this study is to determine if the addition of an individual polygenic risk score (PRS) in addition to the Breast Cancer Risk Assessment Tool (BCRAT) or Tyrer-Cuzick (IBIS) score will aid women at risk of breast…
- Trial name
- GENRE2 (NCT04474834)
- Testing
- Polygenic Risk Score
- Where
- 5 sites in United States
- Volunteers
- 737 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.